Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesComirnaty Original/Omicron BA.4-5

This page is intended as reference information for the general public.

COMIRNATY® Original/Omicron BA.4-5▼ (tozinameran / famtozinameran) COVID-19 mRNA Vaccine

Reference Information

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for COMIRNATY please follow these links:

Great Britain
COMIRNATY Original/Omicron BA.4-5

Northern Ireland
COMIRNATY Original/Omicron BA.4-5

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you are concerned about a side-effect, it can be reported directly via the Coronavirus Yellow Card reporting site or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/lot number if available.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

PP-CMR-GBR-0514 / February 2024
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.